NCT00803543View on ClinicalTrials.gov

Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding

NACompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
HIVHIV Infections
Interventions
DRUG

Valacyclovir

500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks

DRUG

Placebo

Dosage: Two tablets once a day for 24 weeks

Trial Locations (1)

35294

Community Care Building, Birmingham

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Alabama at Birmingham

OTHER